"id","rationale","uuid:ID","versionIdentifier","instanceType"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","dcba7489-209c-4956-90ad-017451d96077","2","StudyVersion"
